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taking ratios of predicted prevalence rates for obese versus non-obese individuals.
Bootstrapped 95% confidence intervals were generated for prevalence ratios.
RESULTS: Among obese adults the unadjusted prevalence of hypertension was
(34.40%), followed by dyslipidemia (21.87%), diabetes (16.34%) and asthma (6.92%).
Adjusted prevalence of chronic diseases was always higher among obese as com-
pared to non-obese and the entire population. The prevalence ratio for diabetes
was 3.06 (95% C.I: 2.82 – 3.30) at the age of 20 and was 2.20 (95% C.I: 2.09 – 2.31) at 70
years. At any age, obesity increases the likelihood of these conditions by at least
50% as compared to non-obese individuals. CONCLUSIONS: Prevalence ratios in-
dicate that obesity has highest impact on prevalence of diabetes; followed by hy-
pertension, osteoarthritis, dyslipidemia. Study findings suggest that obesity is not
only a disease, but may also be a cause for other chronic disorders. There is a need
to develop effective interventions to combat obesity and thus minimize its impact
on other diseases in the United States.
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OBJECTIVES: Adherence to Food and Drug Administration recommended admin-
istration with adalimumab, etanercept, or infliximab may be variable. Suboptimal
adherence patterns may contribute to health care cost increases. This study esti-
mated incremental health care costs of tumor necrosis factor inhibitor (anti-TNF)
under-utilization from amanaged care perspective.METHODS:Medical/pharmacy
claims from the LifeLink™ Health Plan database were used. Inclusion criteria in-
cluded: index anti-TNF started January 1, 2004-December 31, 2007, age18 years, 2
pre-index rheumatoid arthritis diagnosis codes (ICD-9 code 714.xx), 365 days of
index drug, continuous enrollment 6/12months pre-/post-index. Exclusion criteria
included: switching biologics post-index and selected inflammatory conditions.
Under-utilization events were defined as prescriptions/infusions with 10% less
than recommended dosing for adalimumab (40 mg every other week/weekly with/
withoutmethotrexate), etanercept (50mgweekly), or infliximab (3mg/kg dose and
maintenance infusion interval  56 days). Incremental increases in health care
costs for patients with under-utilization, compared to receiving recommended
dosing, were estimated using cost regression models controlling for refill/infusion
intervals. Models were estimated for a 12-month time horizon and until index drug
discontinuation or loss of enrollment. RESULTS:A total of 4,586 RA patients receiv-
ing adalimumab (N1,255; 27,540 prescriptions), etanercept (N2,242; 48,517 pre-
scriptions), or infliximab (N1,089; 19,656 infusions) were included. Mean lengths
of time (days) patients received adalimumab (856), etanercept (881), and infliximab
(903) were comparable. Proportion of under-utilization events were 16%, 39%, and
2% for adalimumab, etanercept, and infliximab, respectively. Adalimumab or et-
anercept under-utilization was significantly associated with incremental in-
creased health care costs ($2,352 and $879; p0.01) for 12 months and through end
of data ($4,677 and $3,806; p0.01). Infliximabunder-utilizationwas infrequent and
not associated with increased health care costs. CONCLUSIONS: In this analysis,
adalimumab or etanercept under-utilization was associated with increased total
healthcare costs; however, infliximab under-utilization did not have a similar re-
sult. Additional research assessing clinical consequences of under-utilization is
warranted.
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OBJECTIVES:Golimumab is a 50milligram (mg), oncemonthly, injected anti-tumor
necrosis factor alpha therapy for treatment of rheumatoid arthritis, ankylosing
spondylitis and psoriatic arthritis. This study calculated expected costs of annual
golimumab therapy based upon observed dosing patterns within a SPP population
during the first 16 months of golimumab availability. METHODS: Pharmacy and
corresponding eNAVIGATORTM patient care management data were collected by
Diplomat Specialty Pharmacy, Flint, MI for adult patients with a golimumab pre-
scription between 4/24/2009 and 8/24/2010. Datawere analyzed statistically and are
reported as n, %, meanstandard deviation (SD) and median. Costs were modeled
in US dollars using the wholesale acquisition cost (WAC; effective 6/9/2010) of
$1,731.48 per 50 mg. RESULTS: The study included 89 patients. The majority were
female (65%); age 45 years (69%); and reported prior biologic use (56%). A 50 mg
golimumab dose was dispensed in 100% of patients and 100% of all doses. The
mean (SD) interval between golimumab doses was 32.0 14.1 days and the me-
dian was 28 days. The mean golimumab dosing interval in patients reporting bio-
logic use prior to golimumab initiation was 32.915.9 days (meanSD) and was
similar to the mean dosing interval observed in patients reporting no biologic use
prior to golimumab initiation (meanSD: 31.112.1 days; p0.15; NS). Based upon
modeling of these early observations, the average golimumab patient will utilize
approximately 11.4 doses of golimumab annually at a cost of $19,739 (WAC).
CONCLUSIONS: In this SPP population, all patients received 50 mg of golimumab.
The mean and median times between distribution of golimumab doses were 32
days and 28 days, respectively. Based upon the dosing and distribution patterns
observed, the estimated average annual per patient cost of golimumab would be
$19,739. Golimumab utilization may be similar for patients regardless of prior use
of biologic therapies.
PSY62
PERCEIVED BENEFITS AND DISADVANTAGES OF INTRAVENOUS (IV) BIOLOGIC
THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS
Bolge S, Vanderpoel J, Eldridge H, Mody S, Lofland J, Ingham M
Centocor Ortho Biotech Services, LLC, Horsham, PA, USA
OBJECTIVES: To identify perceived benefits and disadvantages of intravenous in-
fusion (IV) biologic therapy among patients with immunology conditions currently
treated with IV biologic medication. METHODS: Semi-structured telephone inter-
views were conducted with patients self-reporting a diagnosis of ankylosing spon-
dylitis, Crohn’s disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, or ulcer-
ative colitis and currently receiving IV biologic therapy. Study protocol and
questionnaire were approved by an independent institutional review board. Pa-
tients rated satisfactionwith current IVmedication on a 7-point Likert scale, where
1 not at all satisfied and 7very satisfied. Patients also discussed benefits and
disadvantages of IV biologic therapy and reasons for IV preference. RESULTS: 405
interviews were conducted. Mean satisfaction was 6.1; 77% rated satisfaction as 6
or 7. The most frequently described benefits of IV therapy related to healthcare
professional monitoring and oversight at time of infusion. More than half of pa-
tients also experience a social benefit of IV administration, including talking to
other patients about experiences (56%) and tying-in other activities with infusion
facility visits (55%). Most commonly described disadvantages of infusion were du-
ration of infusion (41%) and scheduling issues (23%). Of current IV users,most (82%,
n332) prefer an IV medication to a subcutaneous injection. The most common
reasons for IV preference were: not wanting to self-inject (43%), less frequent dos-
ing (34%), and preference for healthcare professional administration (24%). Satis-
faction with medication and perceived benefits varied somewhat by demograph-
ics, immunologic condition, and factors related to treatment. CONCLUSIONS:
Current IV biologic users are highly satisfied with their medications. Patients per-
ceive the additional opportunity for healthcare provider interaction at infusion
facilities as a benefit of thismode of administration. These results support the need
for continued patient access to IV therapeutic options and shared decision-making
between patients and physicians when selecting biologic treatment.
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OBJECTIVES: Infliximab (IFX) is an infusible anti-tumor necrosis factor (anti-TNF)
drug used in the treatment of rheumatoid arthritis (RA), with Food and Drug Ad-
ministration (FDA) recommended administrations of 3 mg/kg at weeks 0, 2, 6, and
every 8 weeks thereafter. Dose increases up to 10 mg/kg or decreases in infusion
intervals to every 4 weeks may be appropriate based on individual response. Lim-
ited data are available presenting weight-based dosing, total quantity adminis-
tered, and infusion intervals simultaneously over the course of 30 infusions. The
objective of this studywas to calculateweight-based dosing, total quantity infused,
and infusion intervals for RA patients receiving IFX. METHODS: An event-level
analysis was conducted using medical/pharmacy claims from the IMS LifeLink™
Health Plan database. Inclusion criteria included: IFX initiation January 1, 2004-
December 31, 2007 (i.e., index date); patient age18 years old; 2 RA diagnosis codes
(ICD-9 714.xx); and 365 days of IFX persistence (i.e., number of days between first
and last IFX treatment). Patients were excluded if they had: psoriatic arthritis
(ICD-9 696.0), psoriasis (ICD-9 696.1), ulcerative colitis (ICD-9 556.xx), Crohn’s dis-
ease (ICD-9 555.xx), or ankylosing spondylitis (ICD-9 720.0); evidence of any anti-
TNF during the 6 months prior to index date; or evidence of taking abatacept or
rituximab while on IFX. RESULTS: There were 19,656 IFX infusion events (N1,089)
identified. Themedian weight-based doses spanned 3.0-4.2 mg/kg. Overall median
quantity infused at each infusion spanned 330-477 mg. Median infusion intervals
spanned 50-56 days for infusions 4-20. The median infusion intervals spanned
44-50 days for infusions 21-30. CONCLUSIONS: The observed IFX administration
schedule was consistent with FDA-approved prescribing of weight-based dosing
and infusion intervals over the course of 30 infusions. These data contribute to the
published literature by describing a consistent real-world administration schedule
over a longer period of time compared to other published studies.
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OBJECTIVES: Golimumab is the first and only monthly subcutaneous fully human
anti-TNF approved in the treatment of rheumatoid arthritis (RA), psoriatic arthritis
(PsA), and ankylosing spondylitis (AS). This study evaluated co morbidities and
pre-index biologic use among patients who received golimumab in the GE Centric-
ity® electronic medical records (EMR) database.METHODS: Longitudinal EMR data
were collected from outpatient practices in the United States. It contains clinical
information on over 15 million patients through September 2010. Patients were
selected based on the following criteria: 1ICD-9 diagnosis of RA, PsA, or AS; 18
years of age at the time of the first diagnosis; data 6-months prior and 3-months
after a prescription record of the first biologic, and at least one prescription record
for golimumab. Biologic experience was defined as use of a biologic within 6
months prior to the first golimumab record. RESULTS: A total of 153 [118 (RA); 20
(PsA); 15 (AS)] patients receiving golimumab were identified as meeting all the
inclusion criteria. The mean age was 49 years and 75% were female; 101 (66%)
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patients were biologic-experienced, and 52 (34%) were biologic-naïve before initi-
ating golimumab. A higher percentage of female patients were in the bio-experi-
enced category (70% vs. 55%). Osteoarthritis (27%), hypertension (24%), dyslipide-
mia (17%), and depressive disorders (14%) were the most common comorbidities
prior to the start of golimumab. A higher rate of depressive disorder was observed
in the biologic-experienced group. Baseline mean C-reactive protein test values
were also higher in the biologic-experienced group (3.69 vs. 0.97). Biologic-experi-
enced patients on golimumabwere switchedmostly from adalimumab (n42) and
etanercept (n25). CONCLUSIONS: In this longitudinal EMR, patients receiving
golimumab were more likely to have prior biologic experience. Biologic-experi-
enced patients appeared to have higher C-reactive protein test values and greater
rates of depressive disorders than their biologic-naïve counterparts.
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OBJECTIVES: Golimumab (GLM) is a monthly self-injected anti-tumor necrosis fac-
tor alpha therapy providing once-monthly dosing for patients with rheumatoid
arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). This study
assesses the baseline characteristics and utilization patterns of patients who re-
ceived GLM. METHODS: We performed a retrospective database analysis of The
MarketScan® Research Database from Thomson Reuters. This database contains
individual-level, de-identified, healthcare claims information from employers,
health plans, hospitals, Medicare, and Medicaid. A total of 29,774 patients in this
database had a diagnosis of either RA, PsA or AS and at least one biologic on record
and met the following inclusion criteria: 18 years of age at the time of the first
diagnosis. From this sample, a total of 174 patients had at least one prescription
record for GLM. RESULTS: A total of 174 patients receiving GLM were identified as
meeting all the inclusion criteria; with 128 (RA), 30 (PSA), and 16 (AS). Themean age
was 48 years and 75% of the sample was female. A total of 155 (89%) patients were
bio-experienced and 19 (11%)were bio-naïve before initiating golimumab. A total of
111 patients received at least two GLMdoses. Of the patients with two ormore GLM
doses, the median and mean SD dosing interval was 29.5 days and 33.65  15.56
days. When looking at biologic naïve patients the median and mean SD dosing
interval was 30 days and 35.37  17.63 days versus biologic experienced patients
with a dosing interval of 29 days and 33.15  15.00 days. CONCLUSIONS: In the
MarketScan database, the majority of patients with a prescription for GLM was
female and had prior biologic experience. GLM median and mean doses were 29.5
and 33.37 days respectively. Previous biologics experience did not significantly
change the GLM dosing patterns.
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OBJECTIVES: Golimumab, a newer anti-tumor necrosis factor agent used in patients
with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has recom-
mendeddosing of 50mgoncemonthly. The objective of this studywas to describe the
biologic experience and dosing for patients using golimumab in the managed care
setting. METHODS: The IMS LifeLink™ Health Plan database (100 managed care
plans) was utilized to identify patients aged 18 years at index and having an index
golimumab pharmacy claim started between 4/24/2009 (product approval) and 10/31/
2009. Patients were required to have 24 months pre- and  2 months post-index
continuous enrollment with 1 RA, PsA, or AS ICD-9 diagnosis code. Biologic experi-
encewas assessed for the pre-index period. Dosingwas assessed through end of data
or loss of enrollment. RESULTS: A total of 282 patients receiving golimumab were
identified; 72%were female;meanagewas52years.Themajority (73%) of patientshad
pre-index biologic experience. Among the biologic-experienced, 60% received 1
unique biologic, 33% received 2 unique biologics, and 7% received 3 unique biologics
before golimumab. Golimumabpatients had experiencewith various combinations of
abatacept, adalimumab, certolizumab, etanercept, and infliximab.Adalimumabalone
and etanercept aloneweremost frequently used prior to golimumab. The golimumab
dose at each of the first six prescription fills was 50 mg for over 97% of patients. The
mean (median) days between fills spanned 29-33 (29-30) days. CONCLUSIONS: The
majority ofpatients receivinggolimumabwerebiologic-experienced.Observeddosing
was consistent with prescribing recommendations. Consistency in dosing was ob-
served over the first six prescriptions. Despite the history of biologic use, golimumab
patientsdidnothaveanapparent increaseddose requirementupon initiation. Further
research is necessary to confirm these findings in a larger sample size over a longer
duration of follow-up.
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OBJECTIVES: To understand the reasons for initiating an intravenous (IV) biologic
therapy among prior subcutaneous injection (SQ) users, and patient satisfaction
before and after switching.METHODS: Semi-structured telephone interviewswere
conducted with 405 immunology patients currently receiving IV biologic therapy.
Patients rated their level of satisfaction with current or prior medication on a
7-point Likert scale (7Very satisfied; 1not at all satisfied) and reported reasons
for switching from SQ therapy. RESULTS: More than a third (37%) of surveyed IV
biologic patients previously used SQ administration. Of these patients, overall
mean satisfaction with SQ was 3.8, with 32% rating the SQ experience as a 1 or 2.
Current IV satisfaction ratings among prior SQ users was 6.2 (vs. 6.1 for all patients
surveyed). Of prior SQ users, 26% did not self-administer their injections, most
frequently due to: dislike of needles; lack of confidence in own ability to administer
the injection correctly; and/or physical inability to handle the syringe. Of thosewho
did not self-administer SQ, 39% went to a physician’s office for administration.
Primary reasons for switching from SQ to IV administration included lack of effi-
cacy (81%), side effects (21%), cost (10%) and dislike of self injections (9%).
CONCLUSIONS: In this analysis, current IV biologic users appear highly satisfied
with this medication. Dissatisfied SQ users that did not self-administer may offset
potential “convenience” advantages of a SQ. They also switched to IV mostly for
loss of efficacy and appear to be satisfied with an IV. Given the potential for patient
preference differences, there appears a need for expanded treatment choices. In-
volving the patient in shared decision making and providing access to both IV and
SQ modes of administration may be important to optimizing patient satisfaction.
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OBJECTIVES: To evaluate treatment patterns when different definitions of discontin-
uation are used. Anti-tumor necrosis factor therapies including adalimumab (ADA),
etanercept (ETA) and infliximab (IFX) are used to treat rheumatoid arthritis (RA). Ex-
amining discontinuation rates can help understanding of real-world treatment pat-
terns. Different definitions of discontinuation rates have been reported elsewhere.
METHODS: Data between 01/2005-06/2006 were extracted from the i3Innovus data-
base. Inclusion criteria were aged18,1 claim for RA, and no evidence of pre-index
biologic use in the sixmonths prior. Patients were followed for 24months. Discontin-
uationwasdefinedasagap in therapy60or365days following the lastdayssupply.
RESULTS: Total of 1,780 patientswere analyzed: ADA 601 (33.8%); ETA 785 (44.1%);
IFX394 (22.1%). If discontinuationwas defined as a gap in therapy of60 days, 57.2%
of patients treated with ADA discontinued, 57.5% of patients treated with ETA and
37.6% of IFX patients discontinued. If discontinuationwas defined as a gap in therapy
of 365 days, 22.5% of ADA patients discontinued, 17.3% of ETA patients and 18% of
IFX patients discontinued. Of those defined as ‘discontinuers’ after a gap of therapy of
60 days, 49.7 % of ADA patients, 62.1% of ETA patients and 12.8% of IFX patients
restarted their index therapy on average 146.8, 146.5, and 302.4 days from the time of
defined ‘discontinuation’. Significantly fewer IFX patients restarted their index ther-
apy (P0.0001) and the time from defined discontinuation to restart was longer
(p0.0001). CONCLUSIONS: This analysis demonstrates that different discontinua-
tion rates are observed when different definitions of discontinuation are employed.
This may impact the understanding of real-world prescribing patterns. The data also
suggests that patients treated with ADA and ETA experience lengthy gaps in therapy.
Future research is needed to examine gaps in therapy on clinical andhealth economic
outcomes.
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OBJECTIVES: Prior etanercept drug utilization studies have reported, that among
patients with a gap in observed refill time exceeding the recommended refill time,
31%-44%of patients experienced gaps greater than 2weeks.Mean gaps (assessed at
each individual refill period) ranged from 19 to 37 days. Limited comparative data
exist for infliximab. The objective of this modeling analysis was to assess the
impact on drug levels from gaps in prescription refill behavior that may result in
under-dosing. METHODS: Steady state concentration models for etanercept and
infliximab were developed to simulate the effect of missed dosing (i.e., gap in
etanercept prescription refill or infliximab administration interval). Results were
expressed as a percent of steady state trough levels (SSTL) in g/mL, and were
presented to simulate gaps that varied from 1-5 weeks. Population pharmacoki-
netic models for etanercept and infliximab were used to simulate out steady state
concentration profiles. The parameters used in these models were extracted from
recent publications. RESULTS: After a refill or administration gap of one week,
etanercept and infliximab concentrations were at 13% and 73% of SSTL respec-
tively. At two weeks, SSTL were 4% and 55% respectively. Etanercept levels were
effectively non-existent after three weeks, whereas infliximab was at 40% of SSTL.
Clinical implications were not simulated. CONCLUSIONS: SSTL of etanercept de-
clines rapidly with gaps in refills and disappears with gaps as short as three weeks.
Infliximab demonstrates a muchmore gradual decline. Poor patient refill behavior
may have consequences that go beyond declining drug levels, and patient adher-
ence risk should be an integral part of any discussion during shared treatment
decision making.
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